ICON and Fountain Medical Development (FMD) Announce Opening of Laboratory Facility in China
30 Junho 2010 - 5:54AM
Business Wire
ICON Central Laboratories - a division of ICON plc,
(NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced
development services to the pharmaceutical, biotechnology and
medical device industries – today announced the opening of a new
laboratory facility in Tianjin, China, in partnership with Fountain
Medical Development Ltd (FMD). It is the third ICON laboratory in
the Asia-Pacific region.
ICON Central Laboratories China offers 3000 square feet of
laboratory space and is located 70 miles from Beijing in Tianjin –
one of China’s most accessible and technologically advanced cities.
It will deliver site support services to clinical investigators
throughout China and offers overall benefits including shorter
shipping distances between clinical sites and existing laboratory
testing facilities which expedites study completion.
The facility will offer a comprehensive menu of testing services
that includes: chemistry, haematology, coagulation, immunology and
other testing services to meet study-specific requirements. The
laboratory received CAP (College of American Pathologists)
accreditation in May 2010 and is also NGSP Level I Certified.
Commenting on the announcement, Tom O’Leary, President - ICON
Central Laboratories, said: “Our alliance with Fountain Medical
Development (FMD) and the launch of this new facility underlines
our commitment to satisfying our clients’ growing demand for
quality central laboratory services in the Asia-Pacific
region.”
Dan Zheng, CEO, FMD, added: “Partnering with ICON Central
Laboratories gives the FMD team access to the resources, systems
and infrastructure of a large international organisation involved
in the management of both large global trials and localised
studies. In return, our local knowledge and experience will be
utilised by ICON as they work to provide clients with a faster and
more cost efficient service.”
ICON has been operational in the Asia-Pacific region for over 10
years, where it already employs over 800 staff, with existing
laboratory facilities situated in Bangalore and Singapore.
Notes to
Editors:
About ICON plc:
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
employs over 7,300 employees, operating from 71 locations in 39
countries.
For further information, please visit www.iconplc.com
About ICON Central Laboratories
ICON Central Laboratories, a division of ICON plc, provides full
service, global central laboratory services from core facilities in
the U.S., Ireland, Singapore, India and China. An extensive test
menu of safety, esoteric and custom-developed assays, including
global flow cytometry, is complemented by dedicated,
sponsor-specific project teams and a single, comprehensive database
for each study as well as a user-friendly, web-based, secure remote
data access system. ICON Central Laboratories also offers a unique
service to manage and compile laboratory data when a client’s study
requires the use of local laboratories.
For further information, please visit
http://www.iconplc.com/company/service-divisions/icon-central-laboratories/
About Fountain Medical Development Ltd.:
Fountain Medical Development Ltd. is a full service clinical CRO
with primary operation in South East Asia and China. It offers
Phase I to Phase IV clinical services, central lab services, EDC,
regulatory affairs, safety handling and pharmacoeconomic
services.
For further information, please visit www.fountain-med.com
ICON/ICLR-G
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
